Phio Pharmaceuticals Corp
-7.63 %
55.99 %
Yet to be announced
Company Overview
Phio Pharmaceuticals Corp is a biotechnology company developing novel therapeutic treatments using its proprietary self-delivering RNAi (INTASYL™) therapeutic platform. The company focuses on immuno-oncology, targeting tumor cells and various cells of the immune system to improve the efficacy of immunotherapy treatments.
The company is currently in the development phase and does not generate revenue from its products, as they are still in various clinical trial stages. Their primary focus is on advancing their pipeline of therapeutic candidates through research and development.
Revenue Sources
PassAs Phio Pharmaceuticals is still in the research and development phase with no commercial products and zero revenue, this criterion is not applicable at this time. The company's planned products and services are focused on medical treatments, which are considered halal.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $6,000 | $1.67m | - | - | 0.00% | 0.00% |
Based on the financial data from the last four quarters, Phio Pharmaceuticals shows zero interest income and zero interest expense. As the company is pre-revenue and still in R&D phase, this criterion is not applicable at this stage of the company's development.
Operational Ethics
PassAfter reviewing available company information, SEC filings, and public records, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Comments